Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Radiotherapy Combined With Full-course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
NCT07874464Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07874464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874464.